David Berg, ESC 2022: Antithrombotic therapy for patients in critical care with COVID-19, the COVID-PACT study

The COVID-PACT study focused on critically ill patients with coronavirus disease 2019 (COVID-19), assessing the use of antithrombotic therapy. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the purpose and design of the COVID-19 study and how the outcomes will implicate clinical practice. 

The abstract entitled ‘COVID-PACT – Antithrombotic therapy in critically Ill COVID-19 patients’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.

Questions:

1. What were the aims, design and primary findings of the COVID-PACT study? (0:20)
2. What were the primary and secondary outcome measures in terms of safety? (2:26)
3. What were the conclusions of the investigators in terms of the optimum antithrombotic agent, and the implications for clinical practice? (4:16)

Disclosures: David Berg has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ESC 2022

Access more content on COVID-19 here and Thrombosis here